XML 52 R47.htm IDEA: XBRL DOCUMENT v2.4.0.6
Revenues (Narrative) (Details) (USD $)
 3 Months Ended 12 Months Ended
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Product Revenues [Abstract]        
Product revenue, sales allowances $ 400,000      
Net product revenue   47,944,031 50,893,794 44,704,570
Accrued liabilities, current 5,086,400 5,264,806 5,086,400  
Other Revenues [Abstract]        
Other revenues, milestone method   0    
Product Sales Related Accruals - Rebates, Product Returns, Administrative Fees and Service Fees
        
Product Revenues [Abstract]        
Accrued liabilities, current 3,200,000 3,400,000 3,200,000  
Product, Caldolor
        
Product Revenues [Abstract]        
Gross product revenue   1,300,000 300,000 100,000
Net product revenue   992,110 (78,134) 101,499
Product, Acetadote, Generic
        
Product Revenues [Abstract]        
Net product revenue   300,000    
Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods
        
Product Revenues [Abstract]        
Accounts receivable, allowances, current 200,000 200,000 200,000  
Collaborative Arrangement, Federal Small Business Grant Programs
        
Other Revenues [Abstract]        
Other revenues, grants   100,000 100,000 100,000
Collaborative Arrangement, Therapeutic Discovery Project Credit, Federal Grant
        
Other Revenues [Abstract]        
Other revenues, grants       900,000
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. | Acetadote and Caldolor
        
Other Revenues [Abstract]        
Other revenues, proceeds from sale of intangible assets   700,000    
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. | Acetadote and Caldolor | Milestone Method Future Revenue, Receipt of Regulatory Notice Related to Conducting Clinical Trials
        
Other Revenues [Abstract]        
Other revenues, milestone method, future revenue upon achieving milestones   700,000    
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. | Acetadote and Caldolor | Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval of Acetadote and Caldolor in China
        
Other Revenues [Abstract]        
Other revenues, milestone method, future revenue upon achieving milestones   $ 1,100,000